Ascent Pediatrics acetaminophen controlled-release beads NDA expected by end of 1997.
This article was originally published in The Tan Sheet
Executive Summary
ASCENT PEDIATRICS ACETAMINOPHEN CONTROLLED-RELEASE BEADS NDA FILING expected by the end of 1997 pending analysis of Phase III trial results, the company states in an April 25 initial public offering prospectus. Under development as an OTC treatment for pain and fever in children, Pediatemp beads would compete against marketed pediatric medications in liquid or chewable tablet forms, the company reports. As designed, the controlled-release product would enable eight-hour dosing, "rather than the four hours required for currently available products," Ascent states.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning